ArticleInternal medicine journal2026
Phenotyping of acute heart failure with preserved ejection fraction: real-world outcomes in a cohort of older patients.
Article in Internal medicine journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrevious studies have identified distinct subgroups (phenogroups) of patients with heart failure with preserved ejection fraction (HFpEF).
aimsThis study aims to identify distinct phenotypes in older patients with HFpEF hospitalised for acute heart failure (AHF) and investigate the relationship between subgroups and outcomes.
methodsRetrospective, single-center study, including patients ≥65 years hospitalised for AHF over a 4-year period. We used electronic medical records to collect clinical data, including hospital outcomes. Latent class analysis (LCA) was performed to identify clusters of clinical phenogroups. The primary outcome was all-cause in-hospital mortality.
resultsOverall, 770 patients were included. Based on LCA, three phenogroups were identified. Phenogroup 1 (n = 323) had both the lowest burden of comorbidities and N-terminal pro-brain natriuretic peptides (NT proBNP) values. Phenogroup 2 (n = 224) had the oldest patients (median age 82 years), the highest prevalence of women (62%) and atrial fibrillation and the worst right ventricular function. Phenogroup 3 (n = 223) consisted mainly of men (57%) and had a higher prevalence of diabetes, obesity and established cardiovascular disease and the worst renal function. Phenogroups 2 and 3 showed a significantly higher risk of primary outcome than phenogroup 1. In addition, survival analysis showed that phenogroup 2 had the worst prognosis, with more than double the risk of in-hospital death.
conclusionsIn this real-world cohort of older patients with HFpEF hospitalised for AHF, we identified three subgroups with significantly different features and prognoses. Phenomapping may be an effective tool to identify individuals most likely to experience adverse outcomes, providing a basis for phenotype-specific treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.